A subsequent study, also in preclinical models using tumor-to-blood ratios, showed that the tracer could classify HER2 expression levels, with very strong correlations with HER2 expression (r2 = 0.94) and, importantly, with tumor response to T-DM1 [61]. The gene discussed is ERBB2; the disease is neoplasm.